Results of HPE therapy in HP-positive, early-stage gastric DLBCL with and without histologic evidence of MALT origin
| Clinicopathologic characteristic . | Pure (de novo) DLBCL . | DLBCL(MALT) . | P* . |
|---|---|---|---|
| No. of patients | 16 | 34 | |
| HPE rate, % | 100 (16/16) | 94.1 (32/34) | 1.000† |
| pCR rate | |||
| All evaluable patients, % | 68.8 (11/16) | 52.9 (18/34) | .365† |
| HP-eradicated patients | 68.8 (11/16) | 56.3 (18/32) | .404† |
| HP-persistent patients | 0 (0/0) | 0 (0/2) | |
| Depth of gastric wall involvement | |||
| Submucosa or above, % | 100 (5/5) | 80 (8/10) | .524‡ |
| Muscularis propria or beyond, % | 54.5 (6/11) | 29.4 (5/17) | .248‡ |
| Time to pCR§ | |||
| Median (95% CI), mo | 2.1 (0.6-3.7) | 5.0 (2.8-7.5) | .024‖ |
| Follow-up time of complete responders¶ | |||
| Median (95% CI), y | 3.5 (0.7-6.3) | 11.1 (7.8-14.4) | |
| Relapse rate, %¶ | 0 (0/0) | 0 (0/0) |
| Clinicopathologic characteristic . | Pure (de novo) DLBCL . | DLBCL(MALT) . | P* . |
|---|---|---|---|
| No. of patients | 16 | 34 | |
| HPE rate, % | 100 (16/16) | 94.1 (32/34) | 1.000† |
| pCR rate | |||
| All evaluable patients, % | 68.8 (11/16) | 52.9 (18/34) | .365† |
| HP-eradicated patients | 68.8 (11/16) | 56.3 (18/32) | .404† |
| HP-persistent patients | 0 (0/0) | 0 (0/2) | |
| Depth of gastric wall involvement | |||
| Submucosa or above, % | 100 (5/5) | 80 (8/10) | .524‡ |
| Muscularis propria or beyond, % | 54.5 (6/11) | 29.4 (5/17) | .248‡ |
| Time to pCR§ | |||
| Median (95% CI), mo | 2.1 (0.6-3.7) | 5.0 (2.8-7.5) | .024‖ |
| Follow-up time of complete responders¶ | |||
| Median (95% CI), y | 3.5 (0.7-6.3) | 11.1 (7.8-14.4) | |
| Relapse rate, %¶ | 0 (0/0) | 0 (0/0) |
Comparison of discrete variables between pure (de novo) DLBCL and subtotal of DLBCL(MALT).
P values (2-sided) were calculated using the χ2 test.
P values (2-sided) were calculated using the Fisher exact test.
Only patients with successful HPE therapy were included.
P values (2-sided) were calculated using Kaplan-Meier analysis with log-rank test.
For complete responders only; analysis to compare the difference between pure (de novo) DLBCL and DLBCL(MALT) was not made because it was caused by timing of patient accrual but not treatment efficacy.